Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about unit size of repeatable business escalating. Look for comparisons against own past, real and recurring, early stage. In the transcript, management discusses land acquisitions, new communities, orders. They mention "we closed on several opportunistic land deals" and "our second land acquisition in Austin" - that's about expanding footprint, not necessarily larger deals. They talk about "more pockets of opportunity" but not that each deal is bigger. They mention "we have begun to observe more pockets of opportunity" - that's more opportunities, not larger size. They talk about "our recent acquisition of 78 homesites in Vero Beach" - that's a specific deal, but no comparison to past deals size. They mention "we continue to prioritize our search for prime land opportunities" - no escalation of unit size. Orders: net new orders increased 95% year-over-year, but that's volume, not size per order. They mention "revenue from new home orders was up 80% year-over-year" - that's revenue, could be due to volume and price. They don't say average order size increased. They talk about backlog value increased, but that's cumulative. They mention "we have been able to gradually increase our backlog closer to our desired level" - not about size per engagement. They talk about "our second land acquisition in Austin" - that's just a new community, not necessarily larger than first. No mention of deals being individually larger, broader, or longer. No comparison of current deal size to past deal size for same offering. They talk about more opportunities, but not that each is bigger. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.